To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines.

Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" S1577 "Greater Research Opportunities With Tax Help Act (GROWTH Act)", and HR8"American Taxpayer Relief Act of 2012"; adding Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program including such provisions in HR6687 and S3716 "To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the taxable vaccines.

Client expense: $1,590,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Bio-based Products Tax Credit H.R. 4953/S.3491: Qualifying Renewable Chemical Production Tax Credit Act of 2012Vaccine Access/Financing Tax for Seasonal Influenza Funding H.R. 6687/S.3716: A Bill to Amend the Internal Revenue Code of 1986 to Include Vaccines against Seasonal Influenza within the Definition of Taxable Vaccines Tax Reform Therapeutic Discovery Project Tax Credit S.3232: A Bill to Amend the Internal Revenue Code of 1986 and the Patient Protection and Affordable Care Act to Extend, Expand, and Improve the Qualifying Therapeutic Discovery Project Program Capital Formation Investment Incentives H.R. 6599/S.3595: High Technology Small Business Research Incentives Act of 2012 Research & Development Tax Credit Extension Innovative Research and Competitiveness Act (Senator Carper Discussion Draft) Startup Innovation Credit Act (Senator Coons Discussion Draft) American Taxpayer Relief Act (Discussion Draft) S.3521: Family and Business Tax Cut Certainty Act of 2012 Biofuels Production Tax Credit Modification for Algae-based Biofuels Production Tax Credit Extension Investment Tax Credit Options S. 3521: Family and Business Tax Cut Certainty Act of 2012 American Taxpayer Relief Act (Discussion Draft) Renewable Chemicals H.R. 4953/S.3491: Qualifying Renewable Chemical Production Tax Credit Act of 2012

Client expense: $1,910,000 · Firm income: Not reported

Funding for National Institutes of Health National Center for Advancing Translational Sciences (NCATS) S.R. 3295: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2013Vaccine Access/Financing Federal Response to the Rising Rates of Autism Tax for Seasonal Influenza Funding H.R. 6687/S.3716: A Bill to Amend the Internal Revenue Code of 1986 to Include Vaccines against Seasonal Influenza within the Definition of Taxable Vaccines 340B Drug Pricing Program HRSA Implementation of Program Changes Implementation of P.L. No: 111-148: Patient Protection and Affordable Care Act of 2010 Average Manufacturer Price Calculations Therapeutic Discovery Project Tax Credit S.3232: A Bill to Amend the Internal Revenue Code of 1986 and the Patient Protection and Affordable Care Act to Extend, Expand, and Improve the Qualifying Therapeutic Discovery Project Program Drug Safety and Review E-Pedigree and Anti-Counterfeiting (Sens. Michael Bennett/Richard Burr Discuss Draft) Supply Chain Integrity Implementation of P.L. No: 112-144: The Food and Drug Administration Safety and Innovation Act of 2012 Pharmacy Compounding Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Medical Countermeasures, Center for Veterinary Medicine, Scientific Infrastructure) S.R. 2375/H.R. 5973: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013 Independent Payment Advisory Board H.R. 5: Protecting Access to Healthcare Act of 2011 Implementation of P.L. No: 111-148: Patient Protection and Affordable Care Act of 2010 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development, and Procurement S.R. 3295: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2013 Biodefense Research, Development, and Procurement S 1855/H.R. 2405: Pandemic and All Hazards Preparedness Act Reauthorization of 2011 HHS Countermeasures Review TransPacific Partnership Data and Intellectual Property Protections for Pharmaceuticals Regulatory Transparency Reimbursement for Innovative Products Medicare Part B Physician-Administered Products Medicare Part D Prescription Drug Program Sequestration of PDUFA Fees Implementation of P.L. No: 112-25: Budget Control Act Medicaid Rebates

Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687.

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Funding for National Institutes of Health National Center for Advancing Translational Sciences (NCATS) S.R. 3295: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2013 Vaccine Access/Financing Federal Response to the Rising Rates of Autism Tax for Seasonal Influenza Funding H.R. 6687/S.3716: A Bill to Amend the Internal Revenue Code of 1986 to Include Vaccines against Seasonal Influenza within the Definition of Taxable Vaccines 340B Drug Pricing Program HRSA Implementation of Program Changes Implementation of P.L. No: 111-148: Patient Protection and Affordable Care Act of 2010 Average Manufacturer Price Calculations Therapeutic Discovery Project Tax Credit S.3232: A Bill to Amend the Internal Revenue Code of 1986 and the Patient Protection and Affordable Care Act to Extend, Expand, and Improve the Qualifying Therapeutic Discovery Project Program Drug Safety and Review E-Pedigree and Anti-Counterfeiting (Sens. Michael Bennett/Richard Burr Discuss Draft) Supply Chain Integrity Implementation of P.L. No: 112-144: The Food and Drug Administration Safety and Innovation Act of 2012 Pharmacy Compounding Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Medical Countermeasures, Center for Veterinary Medicine, Scientific Infrastructure) S.R. 2375/H.R. 5973: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2013 Independent Payment Advisory Board H.R. 5: Protecting Access to Healthcare Act of 2011 Implementation of P.L. No: 111-148: Patient Protection and Affordable Care Act of 2010 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development, and Procurement S.R. 3295: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2013 Biodefense Research, Development, and Procurement S 1855/H.R. 2405: Pandemic and All Hazards Preparedness Act Reauthorization of 2011 HHS Countermeasures Review TransPacific Partnership Data and Intellectual Property Protections for Pharmaceuticals Regulatory Transparency Reimbursement for Innovative Products Medicare Part B Physician-Administered Products Medicare Part D Prescription Drug Program Sequestration of PDUFA Fees Implementation of P.L. No: 112-25: Budget Control Act Medicaid Rebates

Bio-based Products Tax Credit H.R. 4953/S.3491: Qualifying Renewable Chemical Production Tax Credit Act of 2012 Vaccine Access/Financing Tax for Seasonal Influenza Funding H.R. 6687/S.3716: A Bill to Amend the Internal Revenue Code of 1986 to Include Vaccines against Seasonal Influenza within the Definition of Taxable Vaccines Tax Reform Therapeutic Discovery Project Tax Credit S.3232: A Bill to Amend the Internal Revenue Code of 1986 and the Patient Protection and Affordable Care Act to Extend, Expand, and Improve the Qualifying Therapeutic Discovery Project Program Capital Formation Investment Incentives H.R. 6599/S.3595: High Technology Small Business Research Incentives Act of 2012 Research & Development Tax Credit Extension Innovative Research and Competitiveness Act (Senator Carper Discussion Draft) Startup Innovation Credit Act (Senator Coons Discussion Draft) American Taxpayer Relief Act (Discussion Draft) S.3521: Family and Business Tax Cut Certainty Act of 2012 Biofuels Production Tax Credit Modification for Algae-based Biofuels Production Tax Credit Extension Investment Tax Credit Options S. 3521: Family and Business Tax Cut Certainty Act of 2012 American Taxpayer Relief Act (Discussion Draft) Renewable Chemicals H.R. 4953/S.3491: Qualifying Renewable Chemical Production Tax Credit Act of 2012

Client expense: $2,010,000 · Firm income: Not reported

H.R. 2405/S. 1855 - Pandemic and All-Hazards Preparedness Act Reauthorization, provisions relating to pandemic influenza vaccine development H.R. 2679/S. 1440 - Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early Reauthorization Act, provisions relating to patient safety study and report H.R. 6687/S. 3176 A bill to amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines Issues related to Medicaid coverage and reimbursement of biologics; securing the pharmaceutical distribution system through a federal traceability standard; reimbursement of vaccines and related services; implementation of H.R. 3590/Pub. L. No. 111-148, the Patient Protection and Affordable Care Act; biologics data exclusivity; clinical trial and testing issues; and, debt and deficit reduction proposals on Medicaid federal funding, Medicaid rebates, and Medicare Part D rebates.

Client expense: $190,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" and S1577, "Greater Research Opportunities With Tax Help Act (GROWTH Act)"; and HR8, "American Taxpayer Relief Act of 2012;" adding Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program including such provisions in HR6687 and S3716 "To amend the Internal Revenue Code of 1986 to include vaccines against season influenza within the definition of taxable vaccines."

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1513 and S.810 - Great Ape Protection and Cost Savings Act, provisions related to pre-clinical testing H.R. 1930 and S. 1799 - Access to Appropriate Immunizations for Veterans Act of 2011, provisions related to extending VA performance measure to include all federally recommended vaccine H.R. 2245, S. 296 - Preserving Access to Life-Savings Medicines Act of 2011, provisions related to drug shortages H.R. 2405 and S. 1855 - Pandemic and All Hazards Preparedness Act, provisions relating to influenza vaccine innovative technologies H.R. 2529 and S. 1368 - Restoring Access to Medication Act, provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts H.R. 2674 - 340B Program Improvement Act, provisions related to the 340B program H.R. 4132 - FAST Act, provisions related to accelerated approval and other FDA matters H.R. 4156 amd S. 2281 - Expanding and Promoting Expertise in Rare Treatments Act of 2012, provisions related to strengthening the FDA's ability to seek advice from external experts regarding rare diseases H.R. 4223 and S. 1002 - Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act (SAFE DOSES), provisions related to supply chain security H.R. 4274 - BPCA and PREA Reauthorization Act of 2012, Provisions related to amending title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act H.R. 5651 - Food and Drug Administration Reform Act of 2012, provisions related to user fee reauthorization and FDA reform H.R. 6190 - Asthma Inhalers Relief Act of 2012, provisions relating to the removal of Essential-Use Designation for epinephrine H.R. 6611 - Patients Access to Drugs in Shortage Act of 2012, provisions to promote public notification and provide incentives to reduce drug shortages S. 1584 - Drug Safety and Accountability Act of 2011, provisions related to drug safety S. 1699- Prescription Drug Cost Reduction Act, provisions related to 340B and drug rebates S. 1752 - Freedom to Breath Act of 2011, provisions relating to the removal of Essential-Use Designation for epinephrine S. 2113 - Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act, provisions related to accelerated approval and other FDA matters S. 2236 - Advancing Breakthrough Therapies for Patients Act of 2012, provisions related to FDA regulation S. 2281 - Expanding and Promoting Expertise in Rare Treatments Act, provisions related to FDA regulation S. 2289 - The Better Pharmaceuticals and Devices for Children Act, provisions related to amending the Federal Food, Drug, and Cosmetic Act with respect to pediatric provisions S. 3187 - Food and Drug Administration Safety and Innovation Act of 2012, provisions related to user fee reauthorization and FDA reform PL 111-148, PL 111-152 - Patient Protection and Affordable Care Act, ACA implementation, Independent Payment Advisory Board (IPAB), comparative effectiveness, health information technology, disease prevention/wellness, sunshine and innovation provisions Federal Food, Drug, and Cosmetic Act, section related to FDA and regulation of nicotine replacement therapies Comparative effectiveness policy issues H.R. 6687, To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines

H.R. 6559, To amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities. H.R.6687, To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines (quadravalent vaccines). S.3716, A bill to amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines (quadravalent vaccines).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" S1577 "Greater Research Opportunities With Tax Help Act (GROWTH Act)", and HR8"American Taxpayer Relief Act of 2012"; adding Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program including such provisions in HR6687 and S3716 "To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the taxable vaccines.

Client expense: $1,590,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE